Activity of species-specific antibiotics against Crohnʼs disease–associated adherent-invasive Escherichia coli by Brown, Carla L. et al.
ORIGINAL ARTICLE
Activity of Species-speciﬁc Antibiotics Against Crohn’s
Disease–Associated Adherent-invasive Escherichia coli
Carla L. Brown, BSc, Karen Smith, PhD, Daniel M. Wall, PhD, and Daniel Walker, PhD
Background: Crohn’s disease (CD) is associated with bacterial dysbiosis that frequently includes colonization by adherent-invasive Escherichia coli
(AIEC). AIEC are adept at forming bioﬁlms and are able to invade host cells and stimulate the production of proinﬂammatory cytokines. The use of
traditional antibiotics for the treatment of CD shows limited efﬁcacy. In this study, we investigate the use of species-speciﬁc antibiotics termed colicins
for treatment of CD-associated AIEC.
Methods: Colicin activity was tested against a range of AIEC isolates growing in the planktonic and bioﬁlm mode of growth. Colicins were also tested
against AIEC bacteria associated with T84 intestinal epithelial cells and surviving inside RAW264.7 macrophages using adhesion assays and gentamicin
protection assay, respectively. Uptake of colicins into eukaryotic cells was visualized using confocal microscopy. The effect of colicin treatment on the
production of proinﬂammatory cytokine tumor necrosis factor alpha by macrophages was assessed by an enzyme-linked immunosorbent assay.
Results: Colicins show potent activity against AIEC bacteria growing as bioﬁlms when delivered either as a puriﬁed protein or through a colicin-
producing bacterial strain. In addition, colicins E1 and E9 are able to kill cell-associated and intracellular AIEC, but do not show toxicity toward
macrophage cells or stimulate the production of proinﬂammatory cytokines. Colicin killing of intracellular bacteria occurs after entry of colicin protein
into AIEC-infected macrophage compartments by actin-mediated endocytosis.
Conclusions: Our results demonstrate the potential of colicins as highly selective probiotic therapeutics for the eradication of E. coli from the
gastrointestinal tract of patients with CD.
(Inﬂamm Bowel Dis 2015;0:1–11)
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I ncreased understanding of the relationship between health andthe gut microbiome is changing our fundamental understanding
of the pathogenesis of chronic disease. In some conditions, such as
Crohn’s disease (CD), a link with dysbiosis has been established
in multiple populations and is widely believed to be relevant to
disease pathogenesis.1–3 For other conditions such as diabetes, obe-
sity, rheumatoid arthritis, and asthma, associations between disease
and the composition of the microbiome have also been observed.4–6
The ability to manipulate the microbiome in a targeted and
predictable manner is therefore a potentially powerful tool to treat
a range of chronic conditions.
The use of highly selective species- or genus-speciﬁc
antibiotics such as the colicin-like bacteriocins provides a route
through which speciﬁc bacteria can be targeted within a complex
microbial community, for example, to perform “precision sur-
gery of the microbiome.” This diverse family of bacteriocins is
produced by a range of gram-negative bacteria and includes the
S-type pyocins from Pseudomonas aeruginosa and the well-
characterized colicins from Escherichia coli.7,8 Colicin-like bac-
teriocins are highly potent multidomain protein antibiotics that
are often capable of killing susceptible cells at subnanomolar
(nM) concentrations. They kill cells through either a nuclease
activity that speciﬁcally targets DNA (colicins E2, E7, E8, and
E9), rRNA (colicins E3 and E6), tRNA (colicin D and E5), or
pore-forming activity (colicin E1, S4, N, A, and B) or through
the inhibition of cell wall synthesis (colicin M).9 The speciﬁcity
of colicins is due to their high afﬁnity for a speciﬁc outer mem-
brane protein and the ability to use the Tol and Ton cell envelope
complexes to mediate their active transport across the outer
membrane.10
A potential application of colicins is in the treatment of
CD, for which there is evidence implicating E. coli in disease
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pathogenesis.11–13 CD is a chronic and incurable form of inﬂam-
matory bowel disease of complex etiology that is characterized
by granulomatous inﬂammation and intestinal dysbiosis. Dys-
biosis in patients with CD frequently involves decreased diver-
sity in intestinal bacterial microﬂora.14 Previous studies
analyzing luminal samples and mucosal biopsies have shown
a reduction in the major classes of commensals such as
Firmicutes and Bacteroidetes and increased numbers of the
Proteobacteria, especially E. coli.3,15 Escherichia coli resides
as a nonpathogenic commensal organism in the human gut
and accounts for less than 1% of the fecal microbiota.16
However, studies in multiple populations have shown that
a novel pathotype of E. coli termed adherent-invasive E. coli
(AIEC) are more frequently isolated from the ileal mucosa of
patients with CD relative to healthy individuals.13,17,18 AIEC
comprise approximately 3.58% and 0.9% of ileal and colonic
E. coli, respectively, of healthy subjects; however, in this setting, it
is not shown to translocate the intestinal mucosa barrier.18,19 In
patients with CD, AIEC prevalence ranges from the absence of
to 15.8% of colonic samples and from 6.2% to 18% of ileal sam-
ples. Additionally, recent work reported a prevalence of approxi-
mately 25% for AIEC in patients with ileal CD.20
AIEC strains have the ability to adhere to and invade
epithelial cells and produce extensive bioﬁlms that protect
bacteria from the host immune system and antibiotic ther-
apy.19,21,22 For the ileal isolates, this opportunism is linked to
abnormally increased expression of CEACAM6 receptors in pa-
tients with CD in which AIEC bacteria are able to adhere
through FimH of the bacterial type I pilus.23 Furthermore,
expression of long polar ﬁmbriae by AIEC allows the bacteria
to interact with Peyer’s patches and to translocate across M
cells.24 AIEC have also been shown to survive and replicate
within host macrophages.25,26 The invasion of macrophages by
AIEC stimulates the production of several proinﬂammatory cy-
tokines such as tumor necrosis factor alpha (TNF-a) and inter-
leukin 6.25,26 Furthermore, in the recent work of Small et al,27
persistent AIEC infection was established in streptomycin-
treated mice, which caused the development of CD-like symp-
toms. A plausible model for the development of CD is that
alteration of the gut microbiota through an event such as inﬂam-
mation induced by aberrant immune responses or the adminis-
tration of broad-spectrum antibiotics creates a niche for the
proliferation of the AIEC population. This is both consistent
with the genetic loci associated with CD making the carrier
deﬁcient in the detection and clearance of bacteria and also with
the observations linking increased antibiotic use with an
increased risk of developing CD.28–30
To begin to determine the potential of colicins as
therapeutics for the treatment of AIEC infection associated with
CD, we tested the ability of colicins to kill AIEC in the bioﬁlm,
host cell–associated, and intracellular states. Our data show that
colicins have potent activity against AIEC in the bioﬁlm state
and are able to kill both host cell–associated and intracellular
AIEC. Thus, colicins are potentially useful therapeutics for the
speciﬁc targeting of pathogens such as AIEC, in which mainte-
nance of a “healthy microbiome” is desirable.
MATERIALS AND METHODS
Antimicrobials
The following antibiotics were obtained from Sigma-Aldrich
(Poole, Dorset, UK): ampicillin, ciproﬂoxacin, kanamycin, metro-
nidazole, penicillin–streptomycin, and gentamicin. Colicins E1, E3,
E9, and D were expressed and puriﬁed as previously described.31
Measurement of the LPS content of puriﬁed colicins was performed
using the E-TOXATE kit (Sigma-Aldrich) as previously
described.32 Removal of LPS from puriﬁed colicins was performed
using polymyxin B-agarose columns (Detoxi Gel, Pierce, Leices-
tershire, UK) as previously described.33 Brieﬂy, 1 mL of puriﬁed
colicin E9 (3 mg/mL) was loaded onto each 0.5-mL Detoxi column
and incubated at room temperature for 60 minutes. The protein was
then eluted with endotoxin-free water in 1 mL fractions.
Bacterial Strains, Plasmids, and
Protein Puriﬁcation
The AIEC reference strain LF82, an ileal CD mucosa
associated isolate12 and the additional AIEC strains HM95,
HM419, and HM615,17 colonic CD mucosa–associated isolates
were grown on Luria Bertani (LB) agar plates or in LB broth with
shaking at 378C with the addition of ampicillin for LF82. For the
creation of GFP-expressing LF82, competent cells were trans-
formed with pDM1534 by electroporation as previously described.35
Transformants were selected by plating on LB agar supplemented
with kanamycin (50 mg/mL) and isolating those that exhibited
green ﬂuorescence under UV light. The colicin E9-H575A variant
was created by site-directed mutagenesis using the Stratagene Quik-
Change kit (Stratagene, Cheshire, UK) with the plasmid pCS431
and mutagenesis primers E9H575AF (ACT ACA CCT AAG
CGA GCT ATC GAT ATT CAC CGA GGT AAG) and
E9H575AR CTT ACC TCG GTG AAT ATC GAT AGC TCG
CTT AGG TGT AGT. pAR5, encoding RFP-tagged colicin (coli-
cin E9-RFP), was constructed by ampliﬁcation of the RFP gene
using plasmids RFPF (GTT GAC GTC CAT GGC CTC CAC
CGA GGA CGT CAT CAC CGA) and RFPR (CCA CTG TGC
TCG AGC AGG AAC AGG TGG TGG CGG CCC TCG), diges-
tion of the polymerase chain reaction product with NcoI and XhoI,
and ligation into the corresponding sites of pCS4. Colicin E9-RFP
and colicin E9-H575A were puriﬁed by nickel afﬁnity chromatog-
raphy and gel ﬁltration as described for colicin E9.31
Colicin Spot Test Assay
The antimicrobial spectrum of puriﬁed colicins was tested
against AIEC strains by the overlay spot plate method.36 Brieﬂy,
50 mL of log phase bacterial culture (OD600 ¼ 0.6) was added to
5 mL of molten 0.8% agar and overlaid on an LB agar plate. A
5-mL drop of each colicin was spotted onto the overlay plate.
Plates were dried and incubated for 18 hours at 378C and exam-
ined for zones of inhibition.
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Bioﬁlm Formation by E. coli Isolates
AIEC LF82 bioﬁlms were formed on an MBEC 96-peg
plate platform (Innovotech, Edmonton, AL, Canada). Brieﬂy,
each well of a 96-well ﬂat bottom plate was inoculated with
150 mL of LB containing a 1:100 dilution of an overnight culture
of E. coli that had been grown at 378C with shaking at 200 rpm.
Bacteria were added to the plate in triplicate, and control wells
containing only LB media were included on every plate. The 96-
peg plate was placed on top of the microtiter plate, submerging
all the pegs in the bacterial culture. The isolates were incubated
for 24 hours at 378C on a rocking platform at 20 rpm, to allow
mature bioﬁlms to establish. The 3-dimensional structure of
AIEC LF82 mature bioﬁlms was examined by scanning electron
microscopy. For antibiotic treatment of E. coli bioﬁlms, 24-hour
bioﬁlms were formed as described above and challenged for 1
hour with the antibiotics ciproﬂoxacin and metronidazole and
colicins E1 and E9 in sterile phosphate-buffered saline (PBS) in
a volume of 150 mL in the concentration range of 0.002–200 mg/
mL. All measurements were performed in triplicate, and control
antimicrobial-free bioﬁlms were treated with 150 mL of sterile
PBS. After treatment, the viability of bioﬁlm-associated cells
was tested in comparison with untreated control bioﬁlms using
the metabolic dye 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide (XTT), as previously described.37 To
assess the inhibition of LF82 bioﬁlms by E. coliW3110 harboring
the colicin E1–encoding plasmid, pColE1-K53 (pColE1),38 com-
petition assays were performed. LF82 bioﬁlms were grown for 24
hours as described above, and E. coli W3110 carrying or lacking
pColE1-K53 were grown in LB broth for 18 hours at 378C in the
presence of ciproﬂoxacin (0.001 mg/mL) to induce colicin pro-
duction. At 1, 2, 4, 6, and 24 hours, MBEC pegs were extracted
and sonicated to remove bioﬁlm-forming cells. The number of
surviving LF82 cells was determined by counting colony-
forming units (CFUs) on LB containing ampicillin (50 mg/mL)
to select for growth of LF82. All competition assays were repeated
with bioﬁlms in triplicate.
Eukaryotic Cell Culture
T84 human colonic adenocarcinoma cells were cultured as
previously described.39 Brieﬂy, cells were cultured in a 1:1 mix-
ture of Dulbecco’s Modiﬁed Eagle’s Medium (DMEM; Sigma-
Aldrich) and Ham’s F-12 medium (Invitrogen, Leicestershire,
UK) supplemented with 10% fetal bovine serum (FBS) (Invitro-
gen), 2% penicillin-streptomycin, 2% sodium pyruvate, and 10
mM HEPES (Sigma-Aldrich). Conﬂuent T84 monolayers were
subcultured by trypsin (0.25%) in Ethylenediaminetetraacetic
acid (EDTA) treatment. Cells were grown for 7 days in tissue
culture dishes until a cell monolayer was formed before being
used in assays. Experiments that required infection of T84 cells
were performed using antibiotic-free medium. RAW264.7,
a murine macrophage-like cell line, was cultured in RPMI-
1640 medium (Sigma-Aldrich) supplemented with 10% FBS
(Invitrogen), 2% penicillin-streptomycin, and 2% L-glutamine
(Gibco, Leicestershire, UK). All tissue culture cell lines used
in this study were grown at 378C, 5% CO2. RAW264.7 cells
and T84 cells were seeded as 2 · 105 cells per well in 24-well
plates and on glass coverslips in 6-well plates (Corning, Birmingham,
UK). For infections, RAW264.7 macrophages reached 70% con-
ﬂuency after 18 hours, and for T84 cells, a conﬂuent monolayer
was grown after 5 to 7 days.
Endocytosis Inhibitor Treatments
The following inhibitors were purchased from Sigma-
Aldrich and used as described previously.40 Cytochalasin B was
used at 10 mg/mL, polyinosinic acid was used at 50 mg/mL, dy-
nasore was used at 80 mM, dimethylamiloride dimethylamiloride
(DMA) was used at 500 mM, and mannan was used at 1 mg/mL.
Bacterial Adhesion Assays
To assess the efﬁcacy of colicin killing against AIEC
adhered to intestinal epithelial cells, bacterial adhesion assays
were performed. Brieﬂy, T84 intestinal epithelial cells were
grown in 24-well plates at 378C in 5% CO2 until an epithelial
monolayer was formed. Before adhesion assays, T84 cell mono-
layers were washed with sterile PBS. LF82 bacteria were grown
to OD600 ¼ 0.6 in LB broth and back diluted in DMEM culture
media to a concentration of approximately 108 cells per millili-
ter. Cells were infected with LF82 at a multiplicity of infection
(MOI) of 10 for 3 hours at 378C, 5% CO2. To assess antimicro-
bial killing of adherent bacteria, colicin E9 and antibiotic cipro-
ﬂoxacin were diluted in DMEM culture media to concentrations
of 100 mg/mL and added to separate wells at 15, 30, 45, and
60 minutes after infection. After 3 hours, monolayers were
washed 3 times with sterile PBS to remove nonadherent bacteria
and treated with trypsin (0.25%) in EDTA for 10 minutes at
378C. The cell suspension was removed by aspiration and
homogenized by passing through a 22-gauge needle. Cells were
lysed by sonication, and cell-associated LF82 were serially
diluted and plated on LB agar plates containing ampicillin
(50 mg/mL). Plates were incubated overnight at 378C and CFUs
were counted. All adhesion assays were repeated in triplicate.
For photomicroscopy, T84 cell monolayers were grown on glass
coverslips in 6-well plates for 6 to 8 days. Cells were infected
with LF82 (MOI of 10), and when required, were treated with
puriﬁed colicin E9 (100 mg/mL) 15 minutes after infection. After
3 hours, monolayers were washed 3 times with sterile PBS and
ﬁxed with 10% methanol in PBS for 10 minutes. Cells were
washed again in sterile PBS as described above and were then
Giemsa stained (20% Giemsa in dH2O) for 20 minutes at room
temperature. Coverslips were washed and mounted on slides
using clear nail varnish solution. Images were captured using
a Zeiss Axioskop microscope attached to a QImaging MicroPub-
lisher 3.3 RTB camera at ·40 magniﬁcation.
Gentamicin Protection Assay
Investigation of colicin activity against intramacrophagic
LF82 was measured by the gentamicin protection assay.41
Before infection, RAW264.7 cell monolayers were washed with
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sterile PBS. RAW264.7 macrophages grown in 24-well plates
were infected with LF82 at an MOI of 50. After 2 hours, infected
macrophages were washed with PBS and exposed to culture
media (RPMI-1640, FBS, L-glutamine) containing gentamicin
(100 mg/mL) to kill extracellular bacteria that had failed to
invade macrophages. After 1 hour, the media was removed
and macrophages were then treated with culture media contain-
ing antimicrobial treatments in the presence of gentamicin
(20 mg/mL) at 378C, 5% CO2. For LF82 growth curves, media
was free from antimicrobial treatments and was replaced every
24 hours. Antimicrobial treatments used were colicin E9, colicin
E1, and antibiotic ciproﬂoxacin (100 mg/mL). After incubation
with antibiotic for the desired time point, RAW264.7 cells were
washed 3 times with sterile PBS. If colicin protein was added,
macrophages were also treated with trypsin (0.25%) in EDTA
for 5 minutes at 378C. This was to ensure that all macrophage-
bound colicin protein was inactivated. The macrophages were
then scraped from the surface of the plate and lysed with 2%
Triton X-100 in PBS for 5 minutes. Recovered intracellular
bacteria were quantiﬁed by plating serial dilutions on LB agar
containing ampicillin. The plates were incubated overnight at
378C, and CFUs were counted. Bacterial survival in
RAW264.7 cells (% survival) were calculated as a percentage
of viable internalized bacteria relative to the number recovered
from untreated cells infected with LF82, considered as 100%.
Fluorescence Microscopy
RAW264.7 macrophages were seeded on glass coverslips
in 6-well plates and grown to conﬂuency for 18 hours at 378C.
Culture media used for infection contained 50 mg/mL kanamycin
to select for growth of GFP-expressing LF82 strain. Where
required, macrophages were infected with LF82-GFP (MOI of
50) for 2 hours and exposed to the culture medium (RPMI-
1640, FBS, L-glutamine, kanamycin) containing gentamicin
(100 mg/mL) for 1 hour to ensure killing of extracellular bacteria.
Cells were then treated with culture media containing colicin E9-
RFP (100 mg/mL) and gentamicin (20 mg/mL) for 24 hours. In-
fected cells were washed 3 times in sterile PBS and treated with
0.25% trypsin in EDTA for 5 minutes at 378C to inactive extra-
cellular colicin E9-RFP. RAW264.7 macrophages were washed as
described above to remove macrophage-bound protein and ﬁxed
with 2% paraformaldehyde in PBS and 0.5 M sucrose for 10 mi-
nutes at room temperature. Fixed cells were permeabilized with
0.5% Triton X-100 for 3 to 5 minutes at room temperature. Actin
cytoskeleton was stained using Alexa-647–labeled phalloidin
(Life Technologies, Leicestershire, UK) and nuclear DNA
was stained with 40,6-diamidino-2-phenylindole (DAPI) (Life
Technologies). Coverslips were air dried and mounted on slides
with Dako Mounting Medium (Dako, Cambridgeshire, UK).
For colicin uptake experiments, macrophages were pretreated
with each inhibitor for 30 minutes and then further incubated
with colicin E9-RFP in the presence of inhibitor for 4 hours.
Slides were examined using a Zeiss LSM410 Laserscan Micro-
scope equipped with a peripheral argon-UV laser. Image
processing was performed using LSM Image Browser software
(Zeiss, Cambridgeshire, UK).
Detection of TNF-a and LDH
Cytotoxicity Assay
Macrophage culture supernatants were harvested from
LF82-infected and antimicrobial-treated RAW264.7 macrophages
at 24, 30, and 40 hours after infection. Supernatants were assayed
for the production of TNF-a using an enzyme-linked immunosor-
bent assay (BioLegend, Cambridge, UK). Optical density was
determined at 450-nm wavelength, and cytokine concentration
was determined as by manufacturer’s instructions. For RAW264.7
macrophages, cytotoxicity was determined by lactate dehydrogenase
(LDH) release. LDH release was measured colorimetrically (BioL-
egend) according to the manufacturer’s protocol. % cytotoxicity ¼
(compound-treated LDH activity 2 spontaneous LDH activity)/
(maximum LDH activity 2 spontaneous LDH activity) · 100.
RESULTS
Colicins Show Activity Against Planktonic and
Bioﬁlm Associated AIEC
The high frequency of recovery of AIEC isolates from
lesions in patients with CD suggests that AIEC may be involved
in the pathogenicity of this disease. To begin to determine
whether colicins could be used as therapeutics to speciﬁcally
target AIEC, we tested the sensitivity of the AIEC reference strain
LF82 to colicins E1, E3, E9, and D. All tested colicins displayed
killing activity against planktonic LF82, with colicin E1 and E9
displaying potent activity down to a concentration of 0.32 mg/mL
(Fig. 1A). However, as AIEC colonizing the mucosa of patients
with CD exist as multilayered bioﬁlms, which generally show
enhanced tolerance to a range of antibiotics, we investigated the
killing activity of colicins against bioﬁlm-associated AIEC bacte-
ria.42 To determine whether colicins were active against AIEC
growing in the bioﬁlm state, mature LF82 bioﬁlms were grown
using the MBEC platform (Fig. 1B).43 Bioﬁlms grown for 24
hours were treated with colicins E1, E9, or the antibiotics cipro-
ﬂoxacin and metronidazole at a range of concentrations. Colicin
E1 displayed a killing activity against LF82 bioﬁlms superior to
that of both ciproﬂoxacin and metronidazole, and the activity of
colicin E9 was similar to that of ciproﬂoxacin but superior to that
of metronidazole (Fig. 1C). After colicin E1 treatment (200 mg/
mL for 1 h), LF82 bioﬁlms showed only 5% survival relative to
untreated controls.
The activity of colicins E1 and E9 was also tested against
additional AIEC strains isolated from patients with CD in the
planktonic and bioﬁlm states (see Fig., Supplemental Digital
Content 1, http://links.lww.com/IBD/A971). Strains HM95,
HM419, and HM615 have been described previously and were
originally isolated from patients with colonic, ileocolonic, and
ileal CD, respectively.17 Strains HM95, HM419, and HM605
showed high levels of susceptibility to colicins E1 and E9 when
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growing in the planktonic state and a similar pattern of suscepti-
bility to colicins E1 and E9, ciproﬂoxacin, and metronidazole in
the bioﬁlm state with the exception of HM615, which showed
reduced sensitivity to colicin E9 and increased sensitivity to met-
ronidazole (see Fig., Supplemental Digital Content 1, http://links.
lww.com/IBD/A971).
Colicins could potentially be delivered to patients with
CD to reduce or eliminate AIEC colonization in the form of
a colicin-producing probiotic. To test the ability of a nonpatho-
genic E. coli colicin–producing strain to kill LF82 bioﬁlms, we
added a colicin E1–producing strain (E. coli W3110 pColE1) to
established LF82 bioﬁlms. Viable LF82 cells were counted after
1, 2, 4, 6, and 24 hours of exposure to the E1-producing strain.
At 1 hour after addition of W3110 pColE1, close to 90% of
LF82 bioﬁlm-associated cells were killed, and this rose to
99.6% after 24 hours (Fig. 2). Addition of E. coliW3110 lacking
the colicin E1–encoding plasmid failed to reduce the survival of
the LF82 bioﬁlm population at any of the time points tested
(Fig. 2). These data show that the concentration of colicin pro-
duced by naturally occurring colicin-producing bacteria is sufﬁ-
cient to eradicate mature E. coli bioﬁlms.
Colicins Show Activity Against AIEC LF82 Cells
Adhered to T84 Intestinal Epithelial Cells
It has been proposed that the initial stages of chronic
AIEC infection involve receptor-mediated bacterial adhesion to
epithelial cells.23 To determine whether colicins are active
against AIEC that are adhered to host cells, we infected mono-
layers of the T84 human intestinal epithelial cell line with LF82
FIGURE 2. Colicin-producing commensal E. coli showed killing activity
against AIEC bioﬁlms. Mature bioﬁlms (24 h) of LF82 were treated with
an E. coli strain W3110, which naturally produces the colicin E1 pro-
tein. Bioﬁlms were treated for 1, 2, 4, 6, and 24 hours, and bioﬁlm-
associated cells were removed from the surface by sonication and
CFUs were counted. As a control, LF82 bioﬁlms were also exposed to
a non-E1 producing E. coli strain W3110 for the same time points. Each
experiment was performed in triplicate. Error bars represent the SD
between replicates. Signiﬁcant differences in killing by W3110 and
W3110 pColE1 were observed at all time points (P , 0.05, unpaired
Student’s t test).
FIGURE 1. Colicins show activity against CD-associated AIEC bacteria.
A, Colicins show activity against AIEC LF82 in the planktonic state.
AIEC reference strain LF82 was grown in planktonic culture, and
puriﬁed colicin E9 and colicin E1 protein were serially diluted 5-fold
(1 mg/mL–0.32 mg/mL) and spotted on molten agar overlay. Zones
of inhibition show killing of LF82 bacteria by colicin. B, Scanning
electron microscopy image of AIEC LF82 multilayered bioﬁlm grown
for 24 hours. Scale bar shown is 50 mm. C, Colicins show activity
against AIEC bioﬁlm-forming cells in vitro. LF82 bioﬁlms were grown
on MBEC platform for 24 hours and treated with antimicrobials ci-
proﬂoxacin and metronidazole and colicin E1 and colicin E9 at dif-
ferent concentrations for 1 hour. Data shown represent mean and
SD. Tests for signiﬁcant differences between antibiotic treatments
were performed using data from an antibiotic concentration of
1.6 mg/mL. At this concentration, signiﬁcant differences between
antibiotic groups were observed by the Kruskal–Wallis test (P ,
0.05). Pairwise comparisons using the Mann–Whitney test with
a signiﬁcance threshold of P , 0.05, adjusted for multiple compar-
isons using the Bonferroni correction, were used to compare killing
by colicins E1 and E9 with ciproﬂoxacin and metronidazole at this
concentration. At this signiﬁcance, threshold killing of LF82 by coli-
cin E1 was better than by either ciproﬂoxacin or metronidazole.
Killing by colicin E9 was signiﬁcantly better than by metronidazole
but was not signiﬁcantly different from killing by ciproﬂoxacin.
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and tested the ability of colicin E9 to kill cell-adhered bacteria
when added 15, 30, 45, and 60 minutes after infection. On
addition of colicin E9 at 15, 30, and 45 minutes after infection,
live and adhered LF82 could no longer be detected by CFU
counts (Fig. 3). Colicin treatment at 1 hour after infection caused
a 2-log unit reduction in CFU counts of cell associated LF82
compared with untreated controls (Fig. 3). These data show that
colicin E9 can effectively kill AIEC bacteria adhered to human
intestinal epithelial cells.
To determine whether changes in the morphology of
intestinal epithelial cells were induced by AIEC infection and
subsequent colicin treatment, T84 cells were grown on glass
coverslips, infected with LF82, and treated at 15 minutes after
infection with colicin E9, where required. At 3 hours after
infection, T84 monolayers were Giemsa stained and visualized.
Light micrographs showed that LF82 infection of T84 cell
monolayers caused alterations in the cell morphology (Fig. 4).
LF82-infected monolayers displayed high levels of cell detach-
ment and increased production of abnormal cell protrusions and
lamellipodia, indicative of actin remodeling (Fig. 4B).13 Colicin
FIGURE 4. Colicin killing of intestinal epithelial cell–associated AIEC bacteria reduced appearance of abnormal cell morphology induced by
infection. T84 cells were grown on glass coverslips in 6-well plates to form epithelial monolayers and infected with AIEC LF82 (MOI of 10 for 3 h).
For colicin-treated samples, colicin E9 (100 mg/mL) was added 15 minutes after infection. Cells were Giemsa stained and visualized with Zeiss
Axioskop (·40 magniﬁcation). Light micrographs show: (A) untreated control, (B) LF82-infected T84 cells, (C) LF82-infected T84 cells treated with
colicin E9 (100 mg/mL for 3 h), (D) uninfected T84 monolayer treated with colicin E9 (100 mg/mL for 3 h). Scale bar shown is 5 mm. Images
represent 2 independent experiments. La, lamelipodia; MV, membrane vesiculation; nc, nuclei; white arrow, adhered bacteria.
FIGURE 3. Colicins show activity against AIEC strain LF82 adhered to
intestinal epithelial cells. T84 intestinal epithelial cell monolayers were
infected with AIEC LF82 (MOI of 10 for 3 h), and when required, colicin
E9 (100 mg/mL) was added in the presence of AIEC bacteria at 15, 30,
45, and 60 minutes after infection. Cell-associated LF82 numbers were
determined by CFU counts. Data shown represent mean and SE of 3
independent experiments. No CFU counts were detected for E9 15, E9
30, and E9 45 by this method. Comparison of CFUs for untreated and
colicin E9 treated showed a signiﬁcant reduction on colicin treatment
at 60 minutes (P , 0.05, unpaired Student’s t test).
Brown et al Inﬂamm Bowel Dis  Volume 0, Number 0, Month 2015
6 | www.ibdjournal.org
E9 treatment of infected T84 monolayers signiﬁcantly reduced the
production of cell protrusions, and a smoother cell monolayer was
observed (Fig. 4C). LF82-infected T84 monolayers treated with
colicin E9 also showed reduced cell detachment and reduced
levels of debris in the apical supernatant. Addition of colicin E9
only to uninfected T84 cells did not induce changes in the cell
morphology (Fig. 4D).
Colicins Reduce the Persistence of
Intracellular AIEC Within
RAW264.7 Macrophages
Previous studies have shown the ability of LF82 and other
AIEC strains isolated from patients with CD to survive and
replicate within macrophages.25 AIEC infection of these cells
stimulates the production of proinﬂammatory cytokines, most
notably TNF-a.25 We therefore sought to determine whether intra-
macrophagic AIEC could be killed through colicin treatment.
Although previous studies have reported extensive replication of
AIEC strain LF82 within macrophages in vitro, we were unable to
reproduce this result.26,44 However, in our hands, LF82 was able
to infect macrophages and persist intracellularly for extended pe-
riods with viable bacteria being detected after 48 hours (see Fig.,
Supplemental Digital Content 2, http://links.lww.com/IBD/
A972). Bacterial survival in RAW264.7 macrophages was deter-
mined using the gentamicin protection assay.41 RAW264.7 mac-
rophages were infected with LF82 at an MOI of 50 for 2 hours,
treated with gentamicin for 1 hour, and then exposed to antimi-
crobial treatment in the presence of gentamicin for 4 or 24 hours.
Antimicrobial treatments were colicin E1, colicin E9, and colicin
E9-H575A, a variant protein that lacks antibacterial activity
because of a mutation in the active site of the cytotoxic DNase
domain, or ciproﬂoxacin, which has previously been shown to be
highly active against intramacrophagic AIEC.45 For antibiotic-free
controls, the number of bacteria present in RAW264.7 macro-
phages at 4 hours and 24 hours was approximately 1.6 · 104
and 800 CFUs per well, respectively (see Fig., Supplemental
Digital Content 2, http://links.lww.com/IBD/A972). Both colicin
E9- and colicin E1-treated macrophages showed reduced intracel-
lular survival of LF82 within macrophages at both 4 and 24 hours,
but to a lesser extent than ciproﬂoxacin (Fig. 5A). In contrast,
treatment with inactive colicin E9-H575A after gentamicin treat-
ment did not reduce survival of intramacrophagic LF82, which
indicated that the cytotoxic function of the protein was directly
responsible for bacterial killing (Fig. 5A).
Colicins Enter AIEC Containing Compartments
Within Infected RAW264.7 Macrophages
To demonstrate colicin entry into RAW264.7 macrophages,
we constructed a GFP-expressing LF82 strain (LF82-GFP) and
also an RFP-tagged ﬂuorescent colicin E9 (colicin E9-RFP) in
which the DNase domain is replaced with RFP leading to
a cytotoxically inactive protein. RAW264.7 macrophages grown
on glass coverslips in 6-well plates were infected with LF82-GFP
(green) as described above and treated with colicin E9-RFP (red)
FIGURE 5. The cytotoxic function of colicin caused reduced persistence
of intramacrophagic AIEC LF82 bacteria. A, Colicins show activity against
LF82 residing within RAW264.7 macrophages. RAW264.7 macrophages
were infected with LF82 (MOI of 50; 2 h) and treated with gentamicin
(100 mg/mL for 1 h) to kill extracellular bacteria. Antimicrobial treatments
were performed for 24 hours at 100 mg/mL for all tested colicins. At 4
and 24 hours, macrophages were lysed and viable intracellular bacteria
determined by CFU counts. E9H575A is an active site-mutant protein of
colicin E9. Data shown represents mean and SE of 3 independent ex-
periments. One-way ANOVA followed by post hoc analysis with the
Bonferroni correction showed signiﬁcant differences between the
inactive colicin H575A group and colicin E9-, colicin E1-, and cipro-
ﬂoxacin-treated groups at 4 and 24 hours (P , 0.05). B, Colicin enters
LF82-containing compartments in RAW264.7 macrophages. Figure shows
confocal micrographs of RAW264.7 macrophages infected with LF82-GFP
(green) and treated with colicin E9-RFP (red) for 24 hours. Actin is stained
with phalloidin-Alexa 647 conjugate (purple), and nuclear DNA is stained
with DAPI (blue). Scale bars shown are 10 mm. A total number of 50–200
macrophages were assessed per experiment. Confocal micrographs
represent 3 independent experiments. C, Colicin adheres to RAW264.7
macrophages. The ﬁgure shows the ﬂuorescent micrograph of RAW264.7
macrophages treated with colicin E9-RFP for 4 hours. The second panel
shows the DIC image. Scale bar shown is 10 mm.
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and incubated for 24 hours. To selectively visualize intracellular
colicin protein, macrophages were treated with trypsin to
inactivate extracellular and cell-associated colicin E9-RFP pro-
tein. Macrophage cells were extensively washed with PBS to
remove macrophage-bound protein. Using confocal microscopy,
we showed the presence of both colicin protein and LF82 bacteria
within infected macrophages (Fig. 5B). Confocal micrographs
showed that colicin E9-RFP was present within infected
RAW264.7 macrophages, and in some cases, colocalized together
with LF82-GFP within speciﬁc compartments (Fig. 5B).
Although colocalization of colicin with bacteria was detected,
we also detected colicin-RFP protein within macrophages that
was not colocalized with bacteria (see Fig., Supplemental Digital
Content 3, http://links.lww.com/IBD/A973). Interestingly, similar
experiments in which colicin E9-RFP was added to RAW264.7
macrophages that were not subsequently treated with trypsin
showed that the colicin adheres to the surface of the macrophage,
which suggests that colicin could be nonspeciﬁcally taken up by
endocytosis (Fig. 5C). To determine whether this is the case,
macrophages were pretreated with inhibitors of multiple endocytic
pathways, treated with colicin E9-RFP for 4 hours, were trypsin
treated, and washed as described. Confocal micrographs showed
that pretreatment of macrophage cells with cytochalasin B, an
inhibitor of actin polymerization, signiﬁcantly reduced the uptake
of colicin E9-RFP (Fig. 6). The processes of clathrin-mediated
endocytosis, pinocytosis, mannose receptor–mediated endocyto-
sis, and scavenger receptor–mediated endocytosis inhibited by
dynasore, DMA, mannan, and polyinosinic acid, respectively,
were not shown to inﬂuence colicin uptake. These data indicate
that an actin-regulated endocytic pathway regulates colicin uptake
into AIEC-infected macrophage compartments (Fig. 6).
Effect of Colicin Treatment on Macrophage
TNF-a Production
In previous in vitro studies, AIEC-infected macrophages
have been shown to produce increased amounts of proinﬂamma-
tory cytokine TNF-a.25 We therefore sought to investigate
whether colicin killing of intramacrophagic AIEC would cause
a decrease in the production of proinﬂammatory cytokines. To
achieve this, RAW264.7 macrophages were infected with AIEC
strain LF82 and treated with colicin E9. For this assay, colicin
protein was further puriﬁed using endotoxin removal columns to
FIGURE 6. Pretreatment of RAW264.7 macrophages with chemical inhibitor of actin polymerization signiﬁcantly reduced uptake of colicin E9-RFP.
Confocal micrographs of RAW264.7 macrophages pretreated with inhibitors of endocytosis (30 min) and then treated with colicin E9-RFP (red) for
4 hours. Inhibitors used were mannan (mannose receptor–mediated endocytosis), dynasore (clathrin-mediated endocytosis), dimethylamiloride
(pinocytosis), polyinosinic acid (scavenger receptor–mediated endocytosis), and cytochalasin B (actin polymerization). Actin was stained with
phalloidin-Alexa 647 conjugate (purple), and nuclear DNA was stained with DAPI (blue). Arrows and circle highlight colicin E9-RFP inside mac-
rophage cells. Scale bars shown are 10 mm. Confocal micrographs represent 2 independent experiments.
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ensure that LPS was extracted from protein fractions. LPS
(1 mg/mL) was used as a control for cytokine release. For cyto-
kine detection, macrophage cell supernatants were removed at 24,
30, and 40 hours, and enzyme-linked immunosorbent assays were
performed for TNF-a. Although colicin E9 did not reduce the
production of TNF-a from LF82-infected macrophages, increased
production of TNF-a was not detected after colicin treatment (Fig.
7A). A similar result was obtained for ciproﬂoxacin-treated LF82-
infected macrophages indicating that at least in this assay, AIEC
killing is not associated with reduced levels of TNF-a. Colicin E9
treatment of uninfected macrophages was shown to produce sim-
ilar levels of TNF-a as the untreated mock controls at all time
points tested (Fig. 7A). LDH assays showed that colicin E9 treat-
ment was not cytotoxic to macrophages. Untreated macrophages
were shown to produce increased amounts of LDH compared with
colicin-treated and LF82-infected cells at 24 hours (Fig. 7B).
DISCUSSION
A range of chronic immune-related diseases such as
inﬂammatory bowel disease, diabetes, and rheumatoid arthritis
are associated with intestinal dysbiosis, and in a subset of patients,
associations with speciﬁc bacterial species have been determined.
For CD, AIEC have been implicated in playing a role in disease
pathogenesis; and for rheumatoid arthritis, a speciﬁc expansion in
the population of Prevotella copri has been observed.46–48 For the
most part, the use of broad-spectrum antibiotics for the treatment
of chronic immune-related disorders, such as CD, generally show
poor efﬁcacy.49 This can itself lead to the development of severe
and life-threatening secondary infections resulting in extended
hospital care and requirement for further treatments.50,51 More-
over, more frequent antibiotic use in early childhood is also linked
to the development of chronic inﬂammatory diseases, most nota-
bly CD and asthma.52,53 This is believed to be due to the altered
(T cell) immune responses caused by antibiotic-induced changes
in the gut ﬂora composition.54,55
A potential alternative treatment for the correction of
dysbiosis is the use of narrow-spectrum antibiotics such as the
colicin-like bacteriocins, which demonstrate several highly
attractive attributes. These include highly targeted killing on
the species level and potent activity. In this work, colicins were
shown to (1) effectively kill drug-resistant AIEC bioﬁlms, (2)
kill AIEC bacteria associated with intestinal epithelial cells, and
(3) kill AIEC bacteria growing intracellularly within macro-
phages. For the latter, colicins entered AIEC-containing
compartments within RAW264.7 macrophages by exploiting
actin-mediated endocytosis.
The use of colicin-like bacteriocins for the treatment of
bioﬁlm-associated bacteria was previously investigated in
a study by Smith et al,56 which showed that pyocins are able
to effectively kill P. aeruginosa in the bioﬁlm state. In this
study, colicins were shown to effectively kill E. coli bioﬁlms
and showed superior killing compared with the commonly used
antibiotics metronidazole and ciproﬂoxacin. Indeed, the ability
of colicins to inhibit bioﬁlms grown by a range of clinical AIEC
isolates (HM95, 419, 615) highlights their potential as a thera-
peutic against diverse infections. For treatment of intestinal
infections of this kind, we envisage that colicin delivery would
take the form of a colicin-producing probiotic. Indeed, we
FIGURE 7. Colicin is noncytotoxic to macrophage cells and fails to
increase the production of TNF-a. TNF-a (A) and LDH (B) production by
RAW264.7 macrophages infected with LF82 (MOI of 50; 3 h) and
treated with E9; ciproﬂoxacin (100 mg/mL) for 24, 30, and 40 hours
after gentamicin treatment. Untreated represents mock infected
control. LPS (1 mg/mL) stimulation of macrophages was the control for
cytokine production. % Cytotoxicity was determined by measurement
of LDH release relative to uninfected controls. Data are expressed as
mean 6 SE of 2 independent experiments. A, ANOVA followed by
post hoc analysis with the Bonferroni correction indicated differences
(P , 0.05) for both untreated and ColE9-treated versus LF82-, LF82 +
ColE9-, LF82 + Cip- and LPS-treated cells at 24, 30, and 48 hours and
no difference (P . 0.05) between untreated and ColE9 treated cells.
B, ANOVA followed by post hoc analysis with the Bonferroni correction
indicated differences (P , 0.05) at 40 hours for untreated versus LF82,
LF82 + ColE9, LF82 + Cip, LPS, and ColE9 but no other signiﬁcant
differences between groups on pairwise comparison.
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demonstrated the ability of a colicin-producing commensal E.
coli to kill the majority of bioﬁlm-associated cells in established
AIEC bioﬁlms. This result indicates that colicin-producing bac-
teria, which can be readily isolated from the healthy gut micro-
biome, may be effective in the treatment of drug-resistant
bioﬁlm-associated infections.57,58 To fully determine the potential
of colicins as a targeted antimicrobial treatment, future work must
investigate the in vivo efﬁcacy of this antibiotic. Speciﬁc targeting
of AIEC bacteria within the gastrointestinal tract by colicins or
colicin-producing bacteria would be highly supportive of this.
Indeed, recent mouse models showing AIEC persistence in the
intestine may represent a suitable model for this work.27,59
The use of narrow-spectrum therapies has been previously
investigated for acute intestinal infections through use of
species-speciﬁc vaccines for EHEC, UPEC, and recurrent Clos-
tridium difﬁcile infection.60,61 Furthermore, recent studies sug-
gest the use of “personalized medicine,” which considers
variations in individual gut proﬁles.62 The manipulation of the
intestinal microbiota is being recognized as potential mechanism
for the modulation of immune responses in the protection
against allergic disease.63 It also represents a highly desirable
method to combat disorders associated with intestinal dysbio-
sis.62 Current therapies of this kind include fecal microbiota
transplant, bacteriophage therapy, and probiotic or prebiotic
therapies. For treatment of inﬂammatory bowel disease, how-
ever, the long-term efﬁcacy and general applicability of such
therapies remain to be proven.64,65
Overall, the selectivity and potent activity of colicins
suggest that they could be used to effectively eradicate a speciﬁc
bacterial pathogen, such as AIEC, while preserving the bacterial
population that constitutes the normal healthy microbiome. In
light of current concerns over antibiotic resistance, they also
represent a novel class of antimicrobials that have the potential
to treat a wide range of resistant gram-negative infections.
Furthermore, because of the availability of diverse colicins,
which target a number of different uptake pathways, the use of
“colicin cocktails” and combination therapies could be used to
limit the emergence of resistance.
ACKNOWLEDGMENTS
The authors are grateful to Barry Campbell (University of
Liverpool) for providing strains HM95, HM419, and HM615 and
Arlette Darfeuille-Michaud (Universite d’Auvergne) for provid-
ing strain LF82. The authors also thank Angela Rinaldi for pro-
viding excellent technical assistance.
REFERENCES
1. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal micro-
biota in patients with Crohn’s disease and their unaffected relatives. Gut.
2011;60:631–637.
2. Gophna U, Sommerfeld K, Gophna S, et al. Differences between tissue-
associated intestinal microﬂoras of patients with Crohn’s disease and
ulcerative colitis. J Clin Microbiol. 2006;44:4136–4141.
3. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of
faecal microbiota in Crohn’s disease revealed by a metagenomic
approach. Gut. 2006;55:205–211.
4. Larsen N, Vogensen FK, van den Berg FWJ, et al. Gut microbiota in
human adults with type 2 diabetes differs from non-diabetic adults. PLoS
One. 2010;5:e9085.
5. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control
metabolic endotoxemia-induced inﬂammation in high-fat diet-induced
obesity and diabetes in mice. Diabetes. 2008;57:1470–1481.
6. Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and
altered gut microbiota in mice lacking toll-like receptor 5. Science. 2010;
328:228–231.
7. Riley MA, Wertz JE. Bacteriocin diversity: ecological and evolutionary
perspectives. Biochimie. 2002;84:357–364.
8. Kleanthous C, Hemmings AM, Moore GR, et al. Immunity proteins and
their speciﬁcity for endonuclease colicins: telling right from wrong in
protein–protein recognition. Mol Microbiol. 1998;28:227–233.
9. Cascales E, Buchanan SK, Duché D, et al. Colicin Biology. Microbiol
Mol Biol Rev. 2007;71:158–229.
10. Lloubes R, Goemaere E, Zhang X, et al. Energetics of colicin import
revealed by genetic cross-complementation between the Tol and Ton
systems. Biochem Soc Trans. 2012;40:1480–1485.
11. Boudeau J, Glasser AL, Masseret E, et al. Invasive ability of an Escher-
ichia coli strain isolated from the ileal mucosa of a patient with Crohn’s
disease. Infect Immun. 1999;67:4499–4509.
12. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent
Escherichia coli strains in ileal mucosa of patients with Crohn’s disease.
Gastroenterology. 1998;115:1405–1413.
13. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of
adherent-invasive Escherichia coli associated with ileal mucosa in
Crohn’s disease. Gastroenterology. 2004;127:412–421.
14. Ott S, Musfeldt M, Wenderoth D, et al. Reduction in diversity of the
colonic mucosa associated bacterial microﬂora in patients with active
inﬂammatory bowel disease. Gut. 2004;53:685–693.
15. Kang S, Denman SE, Morrison M, et al. Dysbiosis of fecal microbiota in
Crohn’s disease patients as revealed by a custom phylogenetic microarray.
Inﬂamm Bowel Dis. 2010;16:2034–2042.
16. Rhodes JM. The role of Escherichia coli in inﬂammatory bowel disease.
Gut. 2007;56:610–612.
17. Martin HM, Campbell BJ, Hart CA, et al. Enhanced Escherichia coli
adherence and invasion in Crohn’s disease and colon cancer. Gastroen-
terology. 2004;127:80–93.
18. Mylonaki M, Rayment N, Rampton D, et al. Molecular characterization of
rectal mucosa-associated bacterial ﬂora in inﬂammatory bowel disease.
Inﬂamm Bowel Dis. 2005;11:481–487.
19. Martinez-Medina M, Aldeguer X, Lopez-Siles M, et al. Molecular diver-
sity of Escherichia coli in the human gut: new ecological evidence sup-
porting the role of adherent-invasive E. coli (AIEC) in Crohn’s disease.
Inﬂamm Bowel Dis. 2009;15:872–882.
20. Dogan B, Suzuki H, Herlekar D, et al. Inﬂammation-associated
adherent-invasive Escherichia coli are enriched in pathways for use of
propanediol and iron and M-cell translocation. Inﬂamm Bowel Dis.
2014;20:1919–1932.
21. Eaves-Pyles T, Allen CA, Taormina J, et al. Escherichia coli isolated from
a Crohn’s disease patient adheres, invades, and induces inﬂammatory
responses in polarized intestinal epithelial cells. Int J Med Microbiol.
2008;298:397–409.
22. Boudeau J, Barnich N, Darfeuille-Michaud A. Type 1 pili-mediated
adherence of Escherichia coli strain LF82 isolated from Crohn’s disease
is involved in bacterial invasion of intestinal epithelial cells. Mol Micro-
biol. 2001;39:1272–1284.
23. Barnich N, Carvalho FA, Glasser AL, et al. CEACAM6 acts as a receptor
for adherent-invasive E. coli, supporting ileal mucosa colonization in
Crohn disease. J Clin Invest. 2007;117:1566–1574.
24. Chassaing B, Rolhion N, de Vallée A, et al. Crohn disease–associated
adherent-invasive E. coli bacteria target mouse and human Peyer’s patches
via long polar ﬁmbriae. J Clin Invest. 2011;121:966–975.
25. Glasser AL, Boudeau J, Barnich N, et al. Adherent invasive Escherichia
coli strains from patients with Crohn’s disease survive and replicate within
macrophages without inducing host cell death. Infect Immun. 2001;69:
5529–5537.
Brown et al Inﬂamm Bowel Dis  Volume 0, Number 0, Month 2015
10 | www.ibdjournal.org
26. Bringer MA, Glasser AL, Tung CH, et al. The Crohn’s disease-associated
adherent-invasive Escherichia coli strain LF82 replicates in mature phag-
olysosomes within J774 macrophages. Cell Microbiol. 2006;8:471–484.
27. Small CLN, Reid-Yu SA, McPhee JB, et al. Persistent infection with
Crohn’s disease-associated adherent-invasive Escherichia coli leads to
chronic inﬂammation and intestinal ﬁbrosis. Nat Commun. 2013;4:1957.
28. Wurzelmann JI, Lyles CM, Sandler RS. Childhood infections and the risk
of inﬂammatory bowel disease. Dig Dis Sci. 1994;39:555–560.
29. Card T, Logan R, Rodrigues L, et al. Antibiotic use and the development
of Crohn’s disease. Gut. 2004;53:246–250.
30. Hildebrand H, Malmborg P, Askling J, et al. Early-life exposures associ-
ated with antibiotic use and risk of subsequent Crohn’s disease. Scand J
Gastroenterol. 2008;43:961–966.
31. Walker D, Mosbahi K, Vankemmelbeke M, et al. The role of electrostatics
in colicin nuclease domain translocation into bacterial cells. J Biol Chem.
2007;282:31389–31397.
32. Maingrette F, Li L, Renier G. C-reactive protein enhances macrophage
lipoprotein lipase expression. J Lipid Res. 2008;49:1926–1935.
33. Gao B, Tsan MF. Endotoxin contamination in recombinant human heat
shock protein 70 (Hsp70) preparation is responsible for the induction of
tumor necrosis factor a release by murine macrophages. J Biol Chem.
2003;278:174–179.
34. Butcher JP, Malcolm J, Benson RA, et al. Effects of Streptococcus mutans
on dendritic cell activation and function. J Dent Res. 2011;90:1221–1227.
35. Dower WJ, Miller JF, Ragsdale CW. High efﬁciency transformation of
E. coli by high voltage electroporation. Nucleic Acids Res. 1988;16:
6127–6145.
36. Fyfe JA, Harris G, Govan JR. Revised pyocin typing method for Pseu-
domonas aeruginosa. J Clin Microbiol. 1984;20:47–50.
37. Smith K, Perez A, Ramage G, et al. Comparison of bioﬁlm-associated cell
survival following in vitro exposure of meticillin-resistant Staphylococcus
aureus bioﬁlms to the antibiotics clindamycin, daptomycin, linezolid, ti-
gecycline and vancomycin. Int J Antimicrob Agents. 2009;33:374–378.
38. Pusley AP. Escherichia coli K12 strains for use in the identiﬁcation and
characterization of colicins. J Gen Microbiol. 1985;131:369–376.
39. Eckmann L, Jung HC, Schurer-Maly C, et al. Differential cytokine expres-
sion by human intestinal epithelial cell lines: regulated expression of
interleukin 8. Gastroenterology. 1993;105:1689–1697.
40. Marina-Garcia N, Franchi L, Kim YG, et al. Clathrin- and dynamin-
dependent endocytic pathway regulates muramyl dipeptide internalization
and NOD2 activation. J Immunol. 2009;182:4321–4327.
41. Falkow S, Small P, Isberg R, et al. A molecular strategy for the study of
bacterial invasion. Rev Infect Dis. 1987;9(suppl 5):S450–S455.
42. Martinez-Medina M, Naves P, Blanco J, et al. Bioﬁlm formation as a novel
phenotypic feature of adherent-invasive Escherichia coli (AIEC). BMC
Microbiol. 2009;9:202.
43. Bardouniotis E, Huddleston W, Ceri H, et al. Characterization of bioﬁlm
growth and biocide susceptibility testing of Mycobacterium phlei using
the MBEC assay system. FEMS Microbiol Lett. 2001;203:263–267.
44. Bringer MA, Billard E, Glasser AL, et al. Replication of Crohn’s disease-
associated AIEC within macrophages is dependent on TNF-[alpha] secre-
tion. Lab Invest. 2012;92:411–419.
45. Subramanian S, Roberts CL, Hart CA, et al. Replication of colonic
Crohn’s disease mucosal Escherichia coli isolates within macrophages
and their susceptibility to antibiotics. Antimicrob Agents Chemother.
2008;52:427–434.
46. Walker A, Sanderson J, Churcher C, et al. High-throughput clone library
analysis of the mucosa-associated microbiota reveals dysbiosis and differ-
ences between inﬂamed and non-inﬂamed regions of the intestine in
inﬂammatory bowel disease. BMC Microbiol. 2011;11:7.
47. Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Pre-
votella copri correlates with enhanced susceptibility to arthritis. ELife.
2013;2:e01202.
48. Graessler J, Qin Y, Zhong H, et al. Metagenomic sequencing of the
human gut microbiome before and after bariatric surgery in obese patients
with type 2 diabetes: correlation with inﬂammatory and metabolic param-
eters. Pharmacogenomics J. 2012;13:514–522.
49. Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy
with clarithromycin, rifabutin, and clofazimine for Crohn’s disease. Gas-
troenterology. 2007;132:2313–2319.
50. Hickson M, D’Souza AL, Muthu N, et al. Use of probiotic Lactobacillus
preparation to prevent diarrhoea associated with antibiotics: randomised
double blind placebo controlled trial. BMJ. 2007;335:80.
51. Meropol SB, Chan KA, Chen Z, et al. Adverse events associated with
prolonged antibiotic use. Pharmacoepidemiol Drug Saf. 2008;17:
523–532.
52. Hviid A, Svanström H, Frisch M. Antibiotic use and inﬂammatory bowel
diseases in childhood. Gut. 2011;60:49–54.
53. Jedrychowski W, Perera F, Maugeri U, et al. Wheezing and asthma may
be enhanced by broad spectrum antibiotics used in early childhood. Con-
cept and results of a pharmacoepidemiology study. J Physiol Pharmacol.
2011;62:189.
54. Brandl K, Plitas G, Mihu CN, et al. Vancomycin-resistant enterococci
exploit antibiotic-induced innate immune deﬁcits. Nature. 2008;455:
804–807.
55. Pulverer G, Ko HL, Beuth J. Immunomodulating effects of antibiotics
inﬂuencing digestive ﬂora [in French]. Pathol Biol (Paris). 1993;41:
753–758.
56. Smith K, Martin L, Rinaldi A, et al. Activity of pyocin S2 against Pseu-
domonas aeruginosa bioﬁlms. Antimicrob Agents Chemother. 2012;56:
1599–1601.
57. Smajs D, Strouhal M, Matejkova P, et al. Complete sequence of low-
copy-number plasmid MccC7-H22 of probiotic Escherichia coli H22
and the prevalence of mcc genes among human E. coli. Plasmid. 2008;
59:1–10.
58. Cursino L, Smajs D, Smarda J, et al. Exoproducts of the Escherichia coli
strain H22 inhibiting some enteric pathogens both in vitro and in vivo.
J Appl Microbiol. 2006;100:821–829.
59. Chassaing B, Koren O, Carvalho F, et al. AIEC pathobiont instigates
chronic colitis in susceptible hosts by altering microbiota composition.
Gut. 2013;63:1069–1080.
60. Svennerholm AM, Lundgren A. Recent progress toward an enterotoxi-
genic Escherichia coli vaccine. Expert Rev Vaccines. 2012;11:495–507.
61. Borody TJ, Peattie D, Campbell J. Therapeutic potential of the human
gastrointestinal microbiome. Drug Dev Res. 2013;74:385–392.
62. Maurice CF, Haiser HJ, Turnbaugh PJ. Xenobiotics shape the physiology
and gene expression of the active human gut microbiome. Cell. 2013;152:
39–50.
63. Ly NP, Litonjua A, Gold DR, et al. Gut microbiota, probiotics, and
vitamin D: interrelated exposures inﬂuencing allergy, asthma, and obe-
sity? J Allergy Clin Immunol. 2011;127:1087–1094.
64. Van Gossum A, Dewit O, Louis E, et al. Multicenter randomized-
controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on
early endoscopic recurrence of Crohn’s disease after lleo-caecal resection.
Inﬂamm Bowel Dis. 2007;13:135–142.
65. Jin D, Zhang H, Sun J. Manipulation of microbiome, a promising therapy
for inﬂammatory bowel diseases. J Clin Cell Immunol. 2014;5:234.
Inﬂamm Bowel Dis  Volume 0, Number 0, Month 2015 Species-speciﬁc Antibiotics Against CD
www.ibdjournal.org | 11
